JAKARTA – PT Kalbe Farma Tbk (KBLF), a pharmaceutical company, gains IDR 3.45 trillion in 2022, shifting 6.7% from IDR 3.23 trillion in 2021. The small jump resulted from annual increase in its revenue.

Quoted from the 2022 Financial Report published Thursday (30/3), sales reached IDR 28.93 trillion, 10.17% year-on-year (yoy) higher than IDR 26.26 trillion. The gross profit also amounted to IDR 11.70 trillion, growing from IDR 11.28 trillion, while its profit before income taxes increased from IDR 4.14 trillion to IDR 4.45 trillion.

The most extensive contributor to the 2022 revenue is the distribution and logistic segment with IDR 10.80 trillion, followed by nutritional products of IDR 7.83 trillion, prescribed drugs of IDR 6.14 trillion, and health products of IDR 4.15 trillion. The largest market in 2022 was still the domestic market that generated IDR 27.24 trillion of revenue, followed by the export market of IDR 1.69 trillion.

In 2021, the distribution and logistic segment contributed IDR 9.75 trillion to the revenue, followed by nutritional products of IDR 7.16 trillion, prescribed drugs of IDR 5.71 trillion, and health products of IDR 3.62 trillion. Domestic sales clocked up to IDR 25.01 trillion, while export generated IDR 1.24 trillion.

The net profit attributable to the parent entity in 2022 rose to IDR 3.38 trillion from IDR 3.18 trillion in 2021, while the profit attributable to non-controller earned IDR 67.87 billion in 2022, jumping from IDR 48.38 billion in 2021. (LK/ZH)